Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific's overall performance is marked by significant growth in critical segments, as evidenced by a 35% year-over-year increase in Watchman sales and a robust 63% growth in electrophysiology (EP) products, indicating strong market demand and share acquisition. The company is projecting organic sales growth of 11-13% for the upcoming quarter, alongside a solid earnings outlook, with GAAP EPS anticipated between $0.48 and $0.52. Additionally, strategic innovations like the Nalu device, along with the ongoing expansion of its interventional oncology and imaging portfolios, are expected to sustain high growth rates, further enhancing the company's financial prospects.

Bears say

Boston Scientific's outlook is negatively impacted by an expected foreign exchange headwind of approximately $0.04 to adjusted earnings for the full year, alongside a revenue forecast indicating only slight growth relative to previous estimates. The firm operates in mature markets with significant exposure to competitive pricing pressures in its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios, which could constrain future growth. Additionally, challenges in the integration of newly acquired companies and the underperformance of key franchises, such as urology, may hinder Boston Scientific's ability to meet internal projections and market consensus.

Boston Scientific (BSX) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 17 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.